{"preliminary_commentary":{"by_channel":{"x_thread":6},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["zongertinib"]],"indication":"resected stage II-IIIB NSCLC harboring HER2 TKD mutations","name":"Beamion LUNG-3","nct_id":"NCT07195695","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=beamion-lung-3-nct07195695. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":null,"label":"Zongertinib treatment arm","type":"EXPERIMENTAL"},{"description":null,"label":"Standard of Care (SoC) treatment arm","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2036-09-02","type":"ESTIMATED"},"conditions":["Non-small Cell Lung Cancer"],"enrollment":{"count":400,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Zongertinib","otherNames":["BI 1810631, Hernexeos®"],"type":"DRUG"},{"name":"Pembrolizumab","otherNames":[],"type":"DRUG"},{"name":"Atezolizumab","otherNames":[],"type":"DRUG"},{"name":"Durvalumab","otherNames":[],"type":"DRUG"},{"name":"Nivolumab","otherNames":[],"type":"DRUG"}],"last_update":"2026-11-02","lead_sponsor":"Boehringer Ingelheim","official_title":"Beamion LUNG-3: A Randomized, Controlled, Multi-center Trial Evaluating Zongertinib as an Adjuvant Monotherapy Compared With Standard of Care in Patients With Early-stage, Resectable Non-small Cell Lung Cancer (Stage II-IIIB) Harboring Tyrosine Kinase Domain Activating HER2 Mutations","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2032-02-26","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Disease-free survival (DFS) by investigator's assessment","timeFrame":"up to 8 years and 5 months"}],"references":[],"start_date":{"date":"2026-01-16","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations","url":"https://clinicaltrials.gov/study/NCT07195695"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/beamion-lung-3-nct07195695"}